ALL NEWS
- Dec 16 2025 LEO Pharma appoints Marika Murto to lead Global Product Strategy
- Dec 15 2025 LEO Pharma submits adolescent label expansion application for Anzupgo® to EMA
- Nov 06 2025 LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook
- Nov 03 2025 LEO Pharma strengthens leadership in medical dermatology with the appointment of Sophie Lamle as Chief Development Officer
- Aug 18 2025 LEO Pharma delivers 7% revenue growth at CER in H1 2025 and achieves key milestones enabling future growth
- Jun 02 2025 LEO Pharma continues to strengthen strategic leadership in medical dermatology with appointment of Helle Hedegaard Juhl as new EVP of Global People & Corporate Affairs
- May 15 2025 LEO Pharma delivers 9% revenue growth at constant exchange rates and doubles adjusted EBITDA margin to 16%
- May 13 2025 To sharpen focus on the global commercialization of strategic products and the external partnership model, LEO Pharma makes changes to leadership
- Apr 14 2025 LEO Pharma and the Parker Institute Partner to Advance Skin Disease Research
- Mar 05 2025 Liisa Hurme and Mark Levick elected to LEO Pharma’s Board of Directors
- Feb 26 2025 LEO Pharma delivers double-digit revenue growth and strong progress for strategic transformation
- Feb 05 2025 DEBRA Research and LEO Pharma Announce Strategic Partnership to Advance Treatments for Rare Skin Diseases
- Jan 29 2025 LEO Pharma Announces Changes to Executive Leadership
- Jan 11 2025 Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
- Nov 07 2024 LEO Pharma gears for growth with senior leadership changes
- Oct 31 2024 LEO Pharma continues to deliver double-digit revenue growth backed by strong dermatology sales
- Oct 11 2024 LEO Pharma commits to net-zero greenhouse gas emissions by 2050
- Aug 26 2024 LEO Pharma delivers 11% revenue growth (CER) in H1 and upgrades financial outlook for the year
- Aug 21 2024 Timber Pharmaceuticals, Inc., a LEO Pharma Company, provides an update on the development program for TMB-001 in congenital ichthyosis
- Jul 31 2024 Change in the Board of Directors of LEO Pharma
- Jul 04 2024 LEO Pharma announces changes to its Global Leadership Team
- Jun 01 2024 Recognized professor joins LEO Pharma to accelerate external innovation
- May 03 2024 Solid start to the year: 13% revenue growth driven by strong performance in dermatology
- Feb 29 2024 LEO Pharma announces annual results 2023
- Jan 23 2024 LEO Pharma finalizes acquisition of key assets from Timber Pharmaceuticals.
- Oct 09 2023 Globally known professor and dermatologist joins LEO Pharma
- Sep 12 2023 LEO Pharma delivers solid first half-year results and strengthens its capital structure
- Aug 28 2023 LEO Pharma announces changes to its Global Leadership Team
- Aug 21 2023 LEO Pharma Signs Agreement to Acquire Timber Pharmaceutical
- Jun 20 2023 LEO Pharma announces changes to its Global Leadership Team
- Mar 14 2023 LEO Pharma adds internationally recognized dermatologist to Global Leadership Team
- Mar 10 2023 LEO Pharma and ICON enter a Strategic Partnership to propel clinical trial execution within medical dermatology
- Mar 09 2023 LEO Pharma announces annual results 2022
- Jan 12 2023 Delivering a financial turnaround of LEO Pharma
- Aug 31 2022 LEO Pharma appoints Paul Navarre new member of its Board of Directors
- Aug 18 2022 LEO Pharma appoints new Chief Financial Officer and Executive Vice President
- Aug 03 2022 LEO Pharma appoints new Executive Vice President of Global Product Supply
- Jun 28 2022 LEO Pharma appoints Elisabeth Svanberg new member of its Board of Directors
- Jun 02 2022 LEO Pharma strengthens its commercial organization
- Apr 21 2022 LEO Pharma’s emission reduction targets validated by the Science Based Targets initiative
- Mar 17 2022 LEO Pharma announces annual results 2021
- Feb 17 2022 LEO Pharma A/S appoints Brian Hilberdink new President of LEO Pharma Inc. United States
- Jan 31 2022 LEO Pharma appoints Christophe Bourdon as new CEO
- Jan 19 2022 LEO Pharma introduces new operating model to increase competitiveness and support future growth
- Jan 05 2022 LEO Pharma convene dermatology experts in global initiative on skin health
- Nov 30 2021 Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma
- Nov 15 2021 LEO Pharma successfully refinances loan facility
- Sep 29 2021 LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials
- Jul 06 2021 LEO Pharma and X-Chem Enter Into Discovery Research Agreement
- Mar 22 2021 LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19 pandemic in 2020
- Dec 15 2020 LEO Pharma strengthens global leadership team with appointment of Jörg Möller as Executive Vice President, Global Research and Development
- Oct 27 2020 LEO Pharma launches #everydaypsoriasis campaign to mark World Psoriasis Day
- Sep 22 2020 LEO Pharma strengthens global leadership team with appointment of new Executive Vice President, Global Therapeutic & Value Strategy
- Aug 30 2020 LEO Pharma sells portfolio of four products to Cheplapharm
- Aug 19 2020 LEO Pharma unveils ambitious 2030 strategy positioning itself for long-term growth driven by innovation
- Aug 18 2020 LEO Pharma strengthens global leadership team with appointment of new EVP People & Communications
- Jun 29 2020 LEO Pharma strengthens global leadership team
- Mar 12 2020 Updates regarding COVID-19
- Nov 20 2019 LEO Pharma launches Open Innovation in Ontario to support the innovation ecosystem in the province
- Nov 18 2019 LEO Pharma launches Open Innovation program and partnership with the University of Victoria in Canada
- Nov 13 2019 Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors
- Nov 06 2019 LEO Science & Tech Hub and Epicore Biosystems Announce Second Phase of Partnership
- Oct 29 2019 LEO Pharma enters into option agreement with Ubiquigent for access to novel compounds
- Oct 23 2019 World Psoriasis Day 2019: LEO Pharma launches new campaign to reduce the stigma surrounding psoriasis
- Jun 30 2019 LEO Pharma completes the acquisition of Bayer’s prescription dermatology business
- Jun 02 2019 LEO Pharma appoints Catherine Mazzacco as new CEO
- May 09 2019 LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management
- Apr 10 2019 LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
- Apr 08 2019 LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology
- Mar 18 2019 LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment
NEWS ARTICLE
LEO Pharma delivers 7% revenue growth at CER in H1 2025 and achieves key milestones enabling future growth
In H1 2025, LEO Pharma delivered robust growth and significantly improved profitability, enabling an increase to the financial outlook for ...
Ballerup, Denmark, 18 August, 2025
2025 H1 ResultsMEDIA INQUIRIES
